BrECADD Chemotherapy Protocol Administration
BrECADD is administered as a 21-day cycle regimen consisting of brentuximab vedotin 1.8 mg/kg IV on day 1, etoposide 150 mg/m² IV on days 2-4, cyclophosphamide 1250 mg/m² IV on day 2, doxorubicin 40 mg/m² IV on day 2, dacarbazine 250 mg/m² IV on days 3-4, and dexamethasone 40 mg orally on days 2-5 1.
Treatment Schedule and Duration
The protocol follows a PET-guided approach after 2 cycles:
- All patients start with 2 cycles of BrECADD (21-day intervals between cycles)
- PET scan performed after cycle 2 (PET2)
- PET2-negative patients (Deauville score ≤2): receive 2 additional cycles (total of 4 cycles)
- PET2-positive patients (Deauville score ≥3): receive 4 additional cycles (total of 6 cycles) 2, 3
Specific Dosing Details
Brentuximab Vedotin Component
- Dose: 1.8 mg/kg IV on day 1
- Maximum dose: 180 mg (for patients >100 kg, calculate based on 100 kg)
- Infusion time: 30 minutes 4
Chemotherapy Components (Day-by-Day)
- Day 1: Brentuximab vedotin 1.8 mg/kg IV
- Day 2:
- Etoposide 150 mg/m² IV
- Cyclophosphamide 1250 mg/m² IV
- Doxorubicin 40 mg/m² IV
- Dexamethasone 40 mg PO
- Days 3-4:
- Etoposide 150 mg/m² IV
- Dacarbazine 250 mg/m² IV
- Dexamethasone 40 mg PO
- Day 5: Dexamethasone 40 mg PO 1
Patient Population and Indications
BrECADD is used for:
Younger Patients (≤60 years)
- Advanced-stage classical Hodgkin lymphoma (Ann Arbor stage III/IV, or stage II with B symptoms plus large mediastinal mass and/or extranodal lesions)
- Demonstrated superior efficacy compared to eBEACOPP with 4-year progression-free survival of 94.3% vs 90.9% 2
Older Patients (61-75 years)
- Same staging criteria as younger patients
- 82% complete remission rate at end of chemotherapy
- 2-year progression-free survival of 91.5% and overall survival of 90.8%
- Feasible with acceptable toxicity profile in this age group 3
Critical Supportive Care Measures
G-CSF Prophylaxis
- Not mandatory but recommended based on institutional guidelines
- In the HD21 trial, approximately 49% of patients received G-CSF prophylaxis
- Consider especially in older patients given high rates of neutropenia 5
Monitoring Requirements
- Complete blood counts: Monitor closely throughout treatment
- PET/CT imaging: After cycle 2 to guide treatment duration
- Neuropathy assessment: Monitor for peripheral neuropathy (common with brentuximab vedotin)
Expected Toxicity Profile
Most Common Grade ≥3 Toxicities
- Leukopenia: 96% in older patients 3
- Thrombocytopenia: 86% 3
- Anemia: 69% 3
- Febrile neutropenia: 55% in older patients 3
Peripheral Neuropathy
- Occurs in 32-35% of patients (mostly grade 1-2)
- Grade 3 neuropathy rare (approximately 2%)
- Most cases resolve after treatment completion 1
Treatment-Related Morbidity
- Significantly lower than eBEACOPP: 42% vs 59% (p<0.0001)
- This represents a major advantage of BrECADD over traditional intensive regimens 2
Key Advantages Over Standard Regimens
BrECADD offers superior risk-to-benefit ratio compared to eBEACOPP:
- Better efficacy: Hazard ratio 0.66 for progression-free survival 2
- Lower toxicity: 42% vs 59% treatment-related morbidity 2
- No bleomycin: Eliminates risk of pulmonary toxicity
- Shorter duration: 4 cycles for PET2-negative patients vs standard 6 cycles
- Limited anthracycline exposure: Particularly beneficial for older patients 3
Important Caveats
- Not approved for patients >75 years: Safety and efficacy data limited beyond this age
- Requires PET capability: Treatment decisions depend on interim PET assessment
- Central review recommended: PET interpretation should ideally be centrally reviewed for consistency
- Dose modifications: May be needed for hepatic or renal impairment (follow FDA label guidance) 4